ABclonal Technology, a provider of reagents used in life science research, has raked in 1.2 billion yuan ($189 million) in a Series D round of financing, the investee announced on Wednesday.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in